Primary hyperoxaluria, type I
Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy
Gene editing, CRISPR, Rare liver disease, Primary hyperoxaluria type 1 (PH1), Funding
Actionable Insights Powered by AI
Gene editing, CRISPR, Rare liver disease, Primary hyperoxaluria type 1 (PH1), Funding